Call Girls Siliguri Just Call 9907093804 Top Class Call Girl Service Available
Drugs for Treating STIs
1. DRUGS USED IN SEXUALLY
TRANSMITTED INFECTION
Dr. Pravin Prasad
M.B.B.S., MD Clinical Pharmacology
Lecturer, Lumbini MedicalCollege
12 July 2018 (28 Ashadh 2075)Thursday
2. BYTHE END OFTHE CLASS, MBBS
SEM IV STUDENTSWILL BE ABLETO:
Understand the term sexually transmitted
infection (STI)
List the conditions included in STI
List the drugs used for the treatment of STI
Appreciate the syndromic approach for the
treatment of STI
Explain the advantages of syndromic approach
3. CHANGINGTERMS: CHANGING
CONCEPT
Venereal Disease (1658)
Venereal (1400s): related to sex
Considered Syphilis and
Gonorrhoea only
Chancroid, Lymphogranuloma
venerum, granuloma inguinale
also included
7. STI: ETIOLOGICAL
CLASSIFICATION
Disease Causative Organism
Non gonococcal
genital infection
Chlamydia trachomatis
Mycoplasma genitalium
Ureoplasma urealyticum
Gardenella vaginalis
Candida albicans
Herpes genitalis Herpes simplex virus
AIDS Human immunodeficiency virus
8. TREATMENT: EARLY SYPHILIS
Drug of Choice:
Benzathine penicillin 2.4 mega units, im, 2
divided doses, one in each buttock
Penicillin sensitive patients:
Doxycycline 100 mg BD for 14 days
Pregnancy:
Erythromycin stearate 2g daily, qid 14
days
9. LATE SYPHILIS (BENIGN,
CARDIOVASCULAR):TREATMENT
Drug of Choice:
Benzathine penicillin (as above) once a
week for 3 consecutive weeks
Penicillin Sensitive:
Doxycycline 100 mg BD for 28 days
Pregnancy:
Erythromycin stearate (as above) for 28
days
17. DRUGS FOR ANTIRETROVIRAL
THERAPY (ART)
Class of Drug Example
Recommended
Dose
ReverseTranscriptase Inhibitors
Nucleoside group
(NRTIs)
Zidovudine 200mgTDS
Didanosine 125 mg BD
Stavudine 30 mg BD
Lamivudine 150 mg BD
18. DRUGS FOR ANTIRETROVIRAL
THERAPY (ART)
Class of Drug Example
Recommended
Dose
ReverseTranscriptase Inhibitors
Non-nucleoside Reverse
Transcriptase Inhibitors
group (NNRTIs)
Nevirapine 200 mg BD
Efavirenz 600 mg OD
Delavirdine 400 mgTDS
19. DRUGS FOR ART
Class of Drug Example
Recommended
Dose
Protease Inhibitors
Saquinavir 1200 mgTDS
Indinavir 800 mgTDS
Ritonavir 600 mg BD
Nelfinavir 750 mgTDS
Lopinavir 400 mg BD
20. HIV/AIDSTREATMENT: NNRTI
BASED REGIMEN
Preferred Regimen:
Efavirenz + Lamivudine + Zidovudine or
Stavudine
Alternative Regimen:
Efavirenz + Lamivudine + Didanosine
Nevirapine + Lamivudine + Zidovudine or
Stavudine or Didanosine
21. HIV/AIDSTREATMENT: PI BASED
REGIMEN
Preferred Regimen:
Lopinavir + Ritonavir + Lamivudine +
Zidovudine or Stavudine
Alternative Regimen:
Indinavir + Lamivudine +
Zidovudine/Stavudine
Indinavir + Ritonavir + Lamivudine +
Zidovudine/Stavudine
23. STI: CLASSIFICATION ACCORDING
TO MANIFESTATIONS
Manifestation Disease
Rash Syphilis
HIV infection
Lymphogranuloma
venereum
Scabies
Itching Scabies
HIV infection
Pediculosis pubis
Nodules Anogenital
warts
Molluscum
contagiosum
24. STI: SYNDROMIC APPROACH
Algorithms for implementation at
peripheral levels:
Syndrome for genital ulcer disease
Syndrome for urethral discharge
Syndrome for vaginal discharge
Syndrome for inguinal bubo
25. STI: ALGORITHM FOR GENITAL
ULCERTREATMENT
Patient complains of genital ulcer
Vesicles found or/and
history of recurrences
Treat for Herpes
Genitalis
Ulcers (no vesicles,
painful/painless)
Treat for syphilis
and chancroid
Examine
27. CONCLUSION
Sexually Transmitted Infection (STI) is a
broader term, includes asymptomatic
cases as well
Can present with diverse symptoms (ulcer,
discharge, swelling)
Syndromic approach has several
advantages for the treatment of STI
Basis of Syndromic Management:
Case management depends on:
Identification of relatively constant combination of symptoms and signs for a particular syndrome
Knowledge of the causative organisms
Awareness of the antimicrobial susceptibility
Formulation of therapeutic regimens which cover the major pathogens responsible for causing a particular syndrome in a particular geographic area
Using socio-demographic and behavioural data in an attempt to identify patients with a higher risk of developing a particular infection
Service needs to be available at peripheral regions where laboratory services are either not available or reporting is delayed